The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2018 Aug 30

PMID 30155495

Citations 21

Authors

Raul Villanueva-Romero

Irene Gutierrez-Canas

Mar Carrion

Selene Perez-Garcia

Iria V Seoane

Carmen Martinez

Rosa P Gomariz

Yasmina Juarranz

Affiliations

Soon will be listed here.

Abstract

Genetic background, epigenetic modifications, and environmental factors trigger autoimmune response in rheumatoid arthritis (RA). Several pathogenic infections have been related to the onset of RA and may cause an inadequate immunological tolerance towards critical self-antigens leading to chronic joint inflammation and an imbalance between different T helper (Th) subsets. Vasoactive intestinal peptide (VIP) is a mediator that modulates all the stages comprised between the arrival of pathogens and Th cell differentiation in RA through its known anti-inflammatory and immunomodulatory actions. This "neuroimmunopeptide" modulates the pathogenic activity of diverse cell subpopulations involved in RA as lymphocytes, fibroblast-like synoviocytes (FLS), or macrophages. In addition, VIP decreases the expression of pattern recognition receptor (PRR) such as toll-like receptors (TLRs) in FLS from RA patients. These receptors act as sensors of pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern (DAMP) connecting the innate and adaptive immune system. Moreover, VIP modulates the imbalance between Th subsets in RA, decreasing pathogenic Th1 and Th17 subsets and favoring Th2 or Treg profile during the differentiation/polarization of naïve or memory Th cells. Finally, VIP regulates the plasticity between theses subsets. In this review, we provide an overview of VIP effects on the aforementioned features of RA pathology.

Citing Articles

The role of neuropeptides in cutaneous wound healing: a focus on mechanisms and neuropeptide-derived treatments.

Xing L, Chen B, Qin Y, Li X, Zhou S, Yuan K Front Bioeng Biotechnol. 2024; 12:1494865.

PMID: 39539691 PMC: 11557334. DOI: 10.3389/fbioe.2024.1494865.

Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Biomedicines. 2023; 11(12).

PMID: 38137330 PMC: 10740779. DOI: 10.3390/biomedicines11123109.

Changes in TRPV1 Expression as Well as Substance P and Vasoactive Intestinal Peptide Levels Are Associated with Recurrence of Pterygium.

Ilhan H, Unal B, Ayaz Y, Erin N Int J Mol Sci. 2022; 23(24).

PMID: 36555331 PMC: 9779225. DOI: 10.3390/ijms232415692.

VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures.

Lamana A, Castro-Vazquez D, de la Fuente H, Triguero-Martinez A, Martinez-Hernandez R, Revenga M Int J Mol Sci. 2022; 23(15).

PMID: 35955723 PMC: 9369218. DOI: 10.3390/ijms23158578.

Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors.

Lu J, Piper S, Zhao P, Miller L, Wootten D, Sexton P Int J Mol Sci. 2022; 23(15).

PMID: 35897648 PMC: 9331257. DOI: 10.3390/ijms23158069.

References

Hu F, Mu R, Zhu J, Shi L, Li Y, Liu X . Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann Rheum Dis. 2013; 73(5):928-36. DOI: 10.1136/annrheumdis-2012-202444. View

Chen G, Hao J, Xi Y, Wang W, Wang Z, Li N . The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+CD25+ T regulatory cells. Scand J Immunol. 2008; 68(6):572-8. DOI: 10.1111/j.1365-3083.2008.02178.x. View

Kharlamova N, Jiang X, Sherina N, Potempa B, Israelsson L, Quirke A . Antibodies to Porphyromonas gingivalis Indicate Interaction Between Oral Infection, Smoking, and Risk Genes in Rheumatoid Arthritis Etiology. Arthritis Rheumatol. 2015; 68(3):604-13. PMC: 4767537. DOI: 10.1002/art.39491. View

Vaahtovuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P . Fecal microbiota in early rheumatoid arthritis. J Rheumatol. 2008; 35(8):1500-5. View

Gomariz R, Arranz A, Juarranz Y, Gutierrez-Canas I, Garcia-Gomez M, Leceta J . Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides. 2007; 28(9):1825-32. DOI: 10.1016/j.peptides.2007.07.005. View

Picchianti Diamanti A, Rosado M, Lagana B, DAmelio R . Microbiota and chronic inflammatory arthritis: an interwoven link. J Transl Med. 2016; 14(1):233. PMC: 4973033. DOI: 10.1186/s12967-016-0989-3. View

Gutierrez-Canas I, Juarranz Y, Santiago B, Martinez C, Gomariz R, Pablos J . Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun. 2007; 22(3):312-7. DOI: 10.1016/j.bbi.2007.09.007. View

Vidya M, Kumar V, Sejian V, Bagath M, Krishnan G, Bhatta R . Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol. 2017; 37(1):20-36. DOI: 10.1080/08830185.2017.1380200. View

Juarranz Y, Gutierrez-Canas I, Santiago B, Carrion M, Pablos J, Gomariz R . Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 2008; 58(4):1086-95. DOI: 10.1002/art.23403. View

10.

Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna M . Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2015; 54(12):2264-72. DOI: 10.1093/rheumatology/kev252. View

11.

Martinez C, Ortiz A, Juarranz Y, Lamana A, Seoane I, Leceta J . Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS One. 2014; 9(1):e85248. PMC: 3883710. DOI: 10.1371/journal.pone.0085248. View

12.

Leceta J, Gomariz R, Martinez C, Carrion M, Arranz A, Juarranz Y . Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation. 2007; 14(3-4):134-8. DOI: 10.1159/000110636. View

13.

Zhou L, Chong M, Littman D . Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009; 30(5):646-55. DOI: 10.1016/j.immuni.2009.05.001. View

14.

Malmstrom V, Catrina A, Klareskog L . The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2016; 17(1):60-75. DOI: 10.1038/nri.2016.124. View

15.

Perry E, Kelly C, Eggleton P, Soyza A, Hutchinson D . The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?. Rheumatology (Oxford). 2014; 53(11):1940-50. DOI: 10.1093/rheumatology/keu195. View

16.

Janssen K, Westra J, Chalan P, Boots A, Smit M, van Winkelhoff A . Regulatory CD4+ T-Cell Subsets and Anti-Citrullinated Protein Antibody Repertoire: Potential Biomarkers for Arthritis Development in Seropositive Arthralgia Patients?. PLoS One. 2016; 11(9):e0162101. PMC: 5008772. DOI: 10.1371/journal.pone.0162101. View

17.

Seoane I, Martinez C, Garcia-Vicuna R, Ortiz A, Juarranz Y, Talayero V . Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis. Sci Rep. 2018; 8(1):2035. PMC: 5794878. DOI: 10.1038/s41598-018-20400-6. View

18.

Wegner N, Wait R, Sroka A, Eick S, Nguyen K, Lundberg K . Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010; 62(9):2662-72. PMC: 2941529. DOI: 10.1002/art.27552. View

19.

Hajishengallis G . Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2014; 15(1):30-44. PMC: 4276050. DOI: 10.1038/nri3785. View

20.

Arleevskaya M, Kravtsova O, Lemerle J, Renaudineau Y, Tsibulkin A . How Rheumatoid Arthritis Can Result from Provocation of the Immune System by Microorganisms and Viruses. Front Microbiol. 2016; 7:1296. PMC: 4987382. DOI: 10.3389/fmicb.2016.01296. View